Urothelial Carcinoma In Situ — Trials

Urothelial Carcinoma In Situ — Trials · CancerIndex

Clinical trials

Registered studies

12 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: AC.TA. S.r.l.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07725796	A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC	not yet recruiting	Phase 1	30	UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.INDUSTRY	1	Jul 24, 2026	clinicaltrials
NCT05375903	A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)	completed	Phase 1	51	UroGen Pharma Ltd.INDUSTRY	3	Jan 14, 2026